# Coloplast A/S

> Clarifo company profile — qualitative business description generated from
> the company's filings. Financial statements, charts and ratios are
> available on Clarifo (https://www.clarifo.com/en/companies/coloplast).

## Overview

Coloplast A/S is a Denmark-based medical technology company focused on intimate healthcare products used in stoma care, continence care, voice and respiratory care, interventional urology, and wound care. Its business is built around disposable and procedure-related products sold through a global healthcare distribution network, with a strong presence in Europe and North America.

## Products & services

• Ostomy care appliances and accessories
• Continence care products
• Voice and respiratory care products
• Interventional urology products
• Advanced wound dressings
• Tissue-based biologics

- **Chronic Care** (60%) — Includes ostomy care and continence care products for long-term intimate healthcare needs.
- **Voice & Respiratory Care** (10%) — Includes laryngectomy and tracheostomy products used in airway and speech rehabilitation.
- **Interventional Urology** (15%) — Includes disposable urology products for urinary management and related procedures.
- **Advanced Wound Dressings** (10%) — Includes wound dressings, skin care, and contract manufacturing products.
- **Biologics** (5%) — Includes tissue-based products such as Kerecis used in wound healing applications.

- Ostomy care appliances and accessories
- Continence care products
- Voice and respiratory care products
- Interventional urology products
- Advanced wound dressings
- Tissue-based biologics

## Customers

Coloplast sells primarily to hospitals, clinics, and healthcare professionals that prescribe or procure its products for patients with chronic and procedure-related conditions. It also serves distributors and care providers that supply home-care patients and long-term users of its devices and consumables.

- **Hospitals and clinics** (primary) — Buy wound care, urology, and airway products used in procedures and treatment pathways.
- **Healthcare professionals** (primary) — Recommend and prescribe stoma, continence, and respiratory products to end patients.
- **Home-care and long-term care providers** (primary) — Purchase recurring consumables for patients managing chronic conditions at home.
- **Distributors and public health systems** (secondary) — Procure products in volume for national reimbursement and healthcare supply chains.
- **Patients and caregivers** (secondary) — Use the products directly for daily intimate healthcare and long-term self-management.

- Hospitals and clinics buying procedure and inpatient products
- Healthcare professionals prescribing chronic care devices
- Home-care and long-term care providers supplying patients
- Distributors serving public and private healthcare systems
- Patients with stomas, continence needs, or airway conditions

## Geography

Coloplast operates globally, with material sales exposure across Europe, the United States, and emerging markets. The annual report highlights strong performance in the US and Europe in several product areas, while also noting sensitivity to currency moves, reimbursement changes, and market conditions in selected countries such as China and Germany.

- Europe is a core market for chronic care and wound care products
- The United States is a key growth market for several product lines
- China is an important exposure in chronic care and biologics
- Germany and the Middle East are relevant for wound dressing rollout
- Emerging markets add growth but increase currency and reimbursement risk

## Strategy

Coloplast’s strategy centers on expanding its position in chronic care and adjacent intimate healthcare categories, while extending its reach in the US and other underpenetrated markets. The company also uses targeted acquisitions and product development to broaden its portfolio, deepen category expertise, and strengthen its presence in selected therapeutic areas.

- **Expand chronic care scale** (medium-term) — Chronic care is the core franchise and drives recurring demand across stoma and continence categories.
- **Increase US penetration** (medium-term) — The US is identified as a significant untapped market for multiple product groups.
- **Broaden portfolio through M&A** (short-term) — Acquisitions add technology, customer access, and new therapeutic niches.
- **Defend leadership in wound and care categories** (medium-term) — Product breadth and clinical relationships help protect share in specialized healthcare niches.

- Grow chronic care through product innovation and market penetration
- Expand the US franchise where management sees underpenetrated demand
- Build adjacent positions in interventional urology and biologics
- Use acquisitions to add technology, customer relationships, and portfolio depth
- Support growth with focused commercial execution in key geographies

## Risks

Coloplast faces reimbursement and market-access risk, especially in biologics where a Medicare reimbursement change affected sales and triggered goodwill impairment. As a medical device business, it is also exposed to clinical adoption cycles, regulatory requirements, pricing pressure, and foreign exchange volatility across its global healthcare markets.

- **Medicare reimbursement change** [critical] — A reimbursement shift in the outpatient setting disrupted sales in Biologics and reduced expected growth.
- **Goodwill impairment** [high] — Acquired businesses are tested against revised revenue and margin assumptions and may require write-downs.
- **Foreign exchange volatility** [medium] — Revenue is translated from multiple currencies into DKK and can be materially affected by USD and GBP moves.
- **Healthcare pricing and reimbursement pressure** [high] — The business depends on payer support and hospital procurement in regulated healthcare systems.
- **Acquisition integration risk** [medium] — Recent acquisitions require integration of technology, customer relationships, and operations.

- Reimbursement changes can quickly affect product demand and segment valuation
- Goodwill and acquired intangibles are exposed to impairment risk
- Foreign exchange moves can reduce reported revenue and earnings
- Healthcare pricing pressure can limit margin and growth
- Clinical adoption and regulatory approvals can delay commercialization

## Accounting

Coloplast’s results are sensitive to revenue allocation across operating segments, acquisition accounting, and impairment testing of goodwill and intangibles. The report also highlights hedge accounting on interest swaps, contingent consideration for acquisitions, and measurement of acquired customer relationships and technology using valuation models that depend on retention, discount rates, and long-term growth assumptions.

- **Goodwill impairment** — Can materially reduce earnings and asset values
- **Purchase price allocation** — Affects goodwill and future amortization
- **Contingent consideration** — Can create earnings volatility
- **Hedge accounting** — Affects financial items and equity reserves
- **Segment reporting** — Important for assessing mix and business momentum

- Goodwill impairment testing can materially change reported earnings
- Acquisition accounting affects goodwill, intangibles, and deferred tax
- Contingent consideration is remeasured as milestones are assessed
- Hedge accounting affects equity and financial items through swaps
- Segment judgments affect how performance is attributed across businesses

---

*Last updated: 2026-10-24T15:03:59.688272+00:00*